Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Valerio Therapeutics
ALVIOCurrent price
0.081 EUR
-0.0012 EUR (-1.46%)
Last closed
0.082 EUR
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
Euronext Paris
Capitalization
13 064 504 EUR
Yield for 12 month
-56.58 %
1Y
3Y
5Y
10Y
15Y
ALVIO
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children. In addition, it is developing VIO-01, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, a chemistry platform for building new molecules, which include OX400, a decoy DNA platform. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. The company was founded in 1997 and is headquartered in Paris, France. Address: 49, boulevard du GEnEral Martial Valin, Paris, France, 75015
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
0.37 EURP/E ratio
–Dividend Yield
–Current Year
+1 796 822 EUR
Last Year
+1 440 453 EUR
Current Quarter
+44 422 EUR
Last Quarter
+44 422 EUR
Current Year
+1 264 763 EUR
Last Year
+927 360 EUR
Current Quarter
-36 935 EUR
Last Quarter
-36 935 EUR
Key Figures ALVIO
1 year
3 years
5 years
10 years
EBITDA
-16 425 954 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-30.61 %
PEG Ratio
–
Return On Equity TTM
-144.56 %
Wall Street Target Price
0.37 EUR
Revenue TTM
1 885 666 EUR
Book Value
0.026 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
24.7 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.14 EUR
Diluted Eps TTM
-0.14 EUR
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ALVIO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALVIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
919:913
Payout Ratio
–
Last Split Date
17.03.2021
Dividend Date
–
Stock Valuation ALVIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
11.6196
Price Sales TTM
6.9283
Enterprise Value EBITDA
-2.186
Price Book MRQ
3.166
Financials ALVIO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ALVIO
For 52 weeks
0.065 EUR
0.2 EUR
50 Day MA
0.082 EUR
Shares Short Prior Month
–
200 Day MA
0.1 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart